Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

cating that the early increase in flares was transient

in this treatment arm before returning to the placebo level.

The reduction of gout flares, by approximately 40%, in the every two-

week dosing arm of these randomized, controlled, clinical trials is

believed to be the first time a urate lowering therapy has demonstrated

a reduction of gout flares versus a placebo.

New results presented from the GOUT 3 study show that for patients who

have been treated with pegloticase continuously for at least 12

months, the frequency of gout flares was reduced to approximately 0.2

flares per three months in the pegloticase every two weeks group, and

0.4 flares per 3 months in the every four weeks group. This represents

a 9-fold and 4-fold reduction in the frequency of gout flares after 12

months of continuous therapy for the every two and every four weeks

groups compared to the flare frequency reported prior to study entry.

Patients and their physicians participating in GOUT 3 study view this

reduction in gout flare frequency as an important clinical benefit and

the Company believes this benefit contributes to their joint decision

to continue therapy.

-- Immunology: The Company previously reported on the immune response to

pegloticase treatment in the GOUT 1 and GOUT 2 studies, showing a high

rate of seroconversion. The presence of anti-pegloticase antibodies

was predictive of a loss of uric acid control and a greater increase in

the risk of infusion reactions, but not a greater severity of infusion

reactions, particularly in the subset of patients with the highest one-

third of antibody titer.

Results of the GOUT 3 study reported confirm that for patients treated

with pegloticase for up to 12 months showed that:

- The overwhelming m

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
(Date:7/24/2014)... Bound Brook, NJ (PRWEB) July 24, 2014 ... expects to manage numerous projects in the MENA region ... delighted to have a preferred provider agreement with DZS ... in the MENA region,” said Global VP of R&D ... "DZS has developed excellent operational practices with a ...
(Date:7/23/2014)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) ... accomplishments. For the second quarter ended ... of $7.0 million, or $0.10 per share, compared to ... share, for the same period in 2013. As of ... marketable securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... ANGELES , July 23, 2014 /PRNewswire-iReach/ -- Think ... cognitive performance for the long term. They are the ... edge of sustained energy as an alternative to the ... Think Drinks on Indiegogo on July 29, 2014, with ... 30-day campaign. Photo - ...
(Date:7/23/2014)... 2014  Having the right people at the table ... business growth and achieving clinical and operational goals. The ... Summit, July 20-22, 2014, in San Diego ... and healthcare experts discussing how partnerships have positively impacted ... & Chief Executive Officer of Cape Regional Medical Center ...
Breaking Biology Technology:SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2
... Optimal for Expansion in Medical Imaging Management , ... BIRMINGHAM, Ala., June 4 Optimal Reading Services Group, ... services for hospitals, imaging centers and radiology groups, announced ... made a substantial investment in Optimal. The investment provides ...
... 4 Ratcliff promoted Jorge Burbano to senior associate and ... this month. The award-winning firm ( ... design and planning services to healthcare, academic and civic clients ... LEED(R) AP, has more than 20 years of architectural design ...
... , , SAN DIEGO, June 4 Neurocrine ... Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences ... Conference in New York. , , The live ... Eastern Time (ET)/10:30 a.m. Pacific Time (PT). The presentation ...
Cached Biology Technology:Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 2Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 3Ratcliff Promotes Jorge Burbano to Senior Associate; Tess Kavanagh and Tony Keung to Associate 2Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference 2
(Date:7/24/2014)... NEW BRUNSWICK, N.J. A yearlong study funded by ... at the Edward J. Bloustein School of Planning and ... property owners in Sandy-affected towns are skeptical about the ... 400 online survey respondents, 45 percent indicated they were ... town affected by Superstorm Sandy would be rebuilt better ...
(Date:7/24/2014)... is available in German . ... 300 million asthma sufferers worldwide, a further 600 million ... of the global population contending with allergic rhinitis (allergic ... also affect other organs and parts of the body ... intestine (in the form of inflammatory bowel diseases such ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... Scientists (AAPS) is a professional, scientific society of ... and other research institutes worldwide. Founded in 1986, ... exchange of knowledge among scientists to enhance their ... programs, on-going education, information resources, opportunities for networking, ...
... has to work 17 times harder to catch the same amount ... were powered by sail, according to new research. Researchers from ... UK Government data on the amount of fish caught and the ... to analyse the change in fish stocks since 1889. ...
... An experienced fruit fly researcher can tell at a glance ... distinct pigmentation pattern on a fly,s body (a type of bristle ... genitalia are dead giveaways. But most of the fly,s body parts ... no idea whether "maleness" or "femaleness" extended to all of the ...
Cached Biology News:Fishing fleet working 17 times harder than in 1880s to make same catch 2Male or female? In flies, some cells can't tell 2Male or female? In flies, some cells can't tell 3
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
EoProbe Eosinophil Staining Kit, 1 Kit...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: